D1, Other Hedgies Eye Biopharma IPO
Lexeo Therapeutics sets terms for its offering at a time when many recent IPOs are trading in the red.
Another fledgling biopharma company is moving ahead with plans to go public despite the overall stock market’s heightened volatility. And a number of hedge fund firms are poised to benefit.
Lexeo Therapeutics set terms Monday for its upcoming initial public offering. The company said it plans to offer nine million shares for between $13 and $15 per share, according to an updated regulatory filing.